The National Institute for Health and Care Excellence (NICE) has recommended natalizumab as a treatment option for some people living with hard to control MS in England.
NICE decides which medicines are available on the NHS in England, and its guidance often influences decisions across the UK. In new final draft guidance, NICE recommends natalizumab for people living with relapsing remitting MS whose condition remains highly active despite completing a full course of at least one disease modifying therapy, and where the short course oral treatment cladribine is not suitable.
Natalizumab is a disease modifying therapy that works by reducing the movement of inflammatory immune cells into the brain, helping to limit damage to nerve tissue.
Natalizumab was already recommended for people with rapidly evolving severe relapsing remitting MS, and this updated guidance broadens access for those whose MS remains highly active despite other treatments.
